MVC-COV1901安全性与免疫原性评估:巴拉圭III期平行组随机双盲阳性对照免疫桥接研究的中期分析结果
在巴拉圭2个中心开展的III期随机双盲阳性对照试验中,1030名18-91岁成人按1:1接种MVC-COV1901或AZD1222。MVC-COV1901在中和抗体滴度上优于AZD1222,血清转化率非劣效;反应原性总体轻微,无归因于MVC-COV1901的严重不良事件。基线血清阴性者奥密克戎中和滴度较野生型低44.5倍,血清阳性者低3.0倍。
要点
- MVC-COV1901中和抗体滴度优于AZD1222,血清转化率非劣效。
- 反应原性总体轻微,无归因于MVC-COV1901的严重不良事件。
- 基线血清阴性者奥密克戎中和滴度较野生型低44.5倍,血清阳性者低3.0倍。
核心结论
- 巴拉圭研究的安全性和免疫原性数据证实了MVC-COV1901此前的结果。
- 既往感染合并接种该疫苗可能对奥密克戎株提供保护,但其持久性仍未知。
研究设计与样本
- III期、平行组、随机、双盲、阳性对照免疫桥接试验,在巴拉圭2个中心开展。
- 18-91岁成人按1:1随机接受MVC-COV1901或AZD1222肌肉注射,按临床试验计划给药。
- 于接种当天及第二剂后14天采集血清样本。
- 共1030名参与者随机分组,安全性数据来自该人群,主要免疫原性数据来自包含225名参与者的符合方案免疫原性(PPI)子集。
主要发现
- 参与者中58%基线血清阳性。
- 与AZD1222相比,MVC-COV1901在中和抗体滴度方面显示优效性,在血清转化率方面显示非劣效性。
- 反应原性总体轻微,无归因于MVC-COV1901的严重不良事件。
- 两种疫苗均诱导以IgG1和IgG3亚类产生为主的Th1偏向应答。
- 基线血清阴性者奥密克戎中和滴度较野生型中和滴度低44.5倍,基线血清阳性者低3.0倍。
关键数值与推荐
- MVC-COV1901对比AZD1222:中和抗体滴度优效,血清转化率非劣效。
- 基线血清阴性者奥密克戎中和滴度较野生型低44.5倍。
- 基线血清阳性者奥密克戎中和滴度较野生型低3.0倍。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data from previous studies of the MVC-COV1901 vaccine, a subunit vaccine against SARS-CoV-2 based on the stable prefusion spike protein (S-2P) adjuvanted with CpG 1018 adjuvant and aluminum hydroxide, suggest that the vaccine is generally safe and elicits a good immune response in healthy adults and adolescents. By comparing with AZD1222, this study adds to the findings from previous trials and further evaluates the breadth of protection offered by MVC-COV1901. METHODS: In this phase 3, parallel group, randomized, double-blind, active-controlled trial conducted in 2 sites in Paraguay, we assigned adults aged 18-91 years in a 1:1 ratio to receive intramuscular doses of MVC-COV1901 or AZD1222 administered as scheduled in the clinical trial. Serum samples were collected on the day of vaccination and 14 days after the second dose. Primary and secondary safety and immunogenicity endpoints were assessed. In addition, other outcomes investigated were cross-reactive immunity against the Omicron strain and the induction of IgG subclasses. RESULTS: A total of 1,030 participants underwent randomization. Safety data was derived from this set while primary immunogenicity data involved a per-protocol immunogenicity (PPI) subset including 225 participants. Among the participants, 58% are seropositive at baseline. When compared against AZD1222, MVC-COV1901 exhibited superiority in terms of neutralizing antibody titers and non-inferiority in terms of seroconversion rates. Reactogenicity was generally mild and no serious adverse event was attributable to MVC-COV1901. Both vaccines have a Th1-biased response predominated by the production of IgG1 and IgG3 subclasses. Omicron-neutralizing titers were 44.5 times lower compared to wildtype-neutralizing titers among seronegative individuals at baseline. This fold-reduction was 3.0 times among the seropositive. CONCLUSION: Safety and immunogenicity data of MVC-COV1901 from the study in Paraguay confirm previous results. The previous infection coupled with vaccination of this vaccine may offer protection against the Omicron strain though its durability is still unknown.
引用
- Torales J, Cuenca-Torres O, Barrios L, et al. An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay. Vaccine. 2022. PMID: 36404171. doi:10.1016/j.vaccine.2022.10.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。